A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508981-13-00

Acronym

LY03010/CT-EUR-102

Enrollment

170

Registered

2024-04-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, Croatia, Portugal

None listed

Source: EU CTIS · Data processed: Feb 4, 2026